This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Charles G. Moertel, MD; Thomas R. Fleming, PhD; John S. Macdonald, MD; Daniel G. Haller, MD; John A. Laurie, MD; Cathy Tangen, MS

JAMA. 1993;270(8):943-947.

Abstract
Objective.
—To determine the effectiveness of carcinoembryonic antigen (CEA) monitoring in detecting surgically curable recurrence of colon cancer.

Design.
—Clinica data were collected from a national surgical adjuvant trial in which CEA monitoring was elective.

Setting.
—Cancer centers, universities, and community clinics.

Patients.
—A total of 1216 patients with resected colon cancer, 1017 (84%) of whom had CEA monitoring.

Main Outcome Measures.
—Sensitivity and specificity of CEA testing for cancer recurrence and CEA-motivated diagnostic and surgical interventions and their end results.

Results.
—Among 417 monitored patients with recurrence, 59% had a preceding elevation of CEA concentration. Sixteen percent of 600 patients without recurrence showed a false-positive test result. Carcinoembryonic antigen testing was most sensitive for hepatic or retroperitoneal metastasis and relatively insensitive for local, pulmonary, or peritoneal involvement. Surgical explorations were performed in 115 patients with CEA elevations, and 47 recurrences, usually hepatic, were resected with curative intent. On the other hand, 38 patients with normal CEA concentrations and 23 patients not monitored also underwent such resections—usually for pulmonary or local recurrence. Of all CEA-monitored patients, 2.3% are alive and disease free more than 1 year after salvage surgery (2.9% of those with CEA elevations and 1.9% of those with no elevations). Of patients with no CEA monitoring, 2.0% are also alive and disease free more than 1 year after salvage surgery.

Conclusions.
—Cancer cures attributable to CEA monitoring are, at best, infrequent. It is questionable whether this small gain justifies the substantial cost in dollars and physical and emotional stress that this intervention may cause for patients.

(JAMA. 1993;270:943-947)

Author Affiliations
From the Mayo Clinic, Rochester, Minn (Dr Moertel); the Fred Hutchinson Cancer Research Center, Seattle, Wash (Dr Fleming and Ms Tangen); Temple University School of Medicine, Philadelphia, Pa (Dr Macdonald); the University of Pennsylvania Cancer Center, Philadelphia (Dr Haller); Grand Forks (ND) Clinic; (Dr Laurie); and the following cooperative groups sponsored by the National Cancer Institute: Eastern Cooperative Oncology Group, North Central Cancer Treatment Group, and Southwest Oncology Group.

Footnotes
Reprint requests to Mayo Clinic, 200 First St SW, Rochester, MN 55905 (Dr Moertel).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Carcinoembryonic Antigen Monitoring in Metastatic Colorectal Cancer: Words of Caution
Fakih
JCO 2008;26:e7-e7.
FULL TEXT  

Soluble Intercellular Adhesion Molecule-1 as a Prognostic Marker for Stage II Colorectal Cancer Patients
Toiyama et al.
Ann. Surg. Oncol. 2008;15:1617-1624.
ABSTRACT | FULL TEXT  

Diagnostic Accuracy of Serum-Carcinoembryonic Antigen in Recurrent Colorectal Cancer: A Receiver Operating Characteristic Curve Analysis
Korner et al.
Ann. Surg. Oncol. 2007;14:417-423.
ABSTRACT | FULL TEXT  

ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
Locker et al.
JCO 2006;24:5313-5327.
ABSTRACT | FULL TEXT  

Individualizing chemotherapeutic treatment of colorectal cancer
Crews
Am J Health Syst Pharm 2006;63:S12-S17.
ABSTRACT | FULL TEXT  

Colorectal Cancer Surveillance: 2005 Update of an American Society of Clinical Oncology Practice Guideline
Desch et al.
JCO 2005;23:8512-8519.
ABSTRACT | FULL TEXT  

ADAM 12 Cleaves Extracellular Matrix Proteins and Correlates with Cancer Status and Stage
Roy et al.
J. Biol. Chem. 2004;279:51323-51330.
ABSTRACT | FULL TEXT  

The Value of Routine Serum Carcino-Embryonic Antigen Measurement and Computed Tomography in the Surveillance of Patients After Adjuvant Chemotherapy for Colorectal Cancer
Chau et al.
JCO 2004;22:1420-1429.
ABSTRACT | FULL TEXT  

Urinary VEGF and MMP Levels As Predictive Markers of 1-Year Progression-Free Survival in Cancer Patients Treated With Radiation Therapy: A Longitudinal Study of Protein Kinetics Throughout Tumor Progression and Therapy
Chan et al.
JCO 2004;22:499-506.
ABSTRACT | FULL TEXT  

Positron Emission Tomography Affects Surgical Management in Recurrent Colorectal Cancer Patients
Desai et al.
Ann. Surg. Oncol. 2003;10:59-64.
ABSTRACT | FULL TEXT  

Nuclear Matrix Protein Alterations Associated with Colon Cancer Metastasis to the Liver
Brunagel et al.
Clin. Cancer Res. 2002;8:3039-3045.
ABSTRACT | FULL TEXT  

Guidelines for follow up after resection of colorectal cancer
Scholefield and Steele
Gut 2002;51:v3-5.
FULL TEXT  

Detection of Hepatic Metastases from Cancers of the Gastrointestinal Tract by Using Noninvasive Imaging Methods (US, CT, MR Imaging, PET): A Meta-Analysis
Kinkel et al.
Radiology 2002;224:748-756.
ABSTRACT | FULL TEXT  

Role of 18F-FDG Dual-Head Gamma-Camera Coincidence Imaging in Recurrent or Metastatic Colorectal Carcinoma
Even-Sapir et al.
JNM 2002;43:603-609.
ABSTRACT | FULL TEXT  

Osteopontin Identified as Lead Marker of Colon Cancer Progression, Using Pooled Sample Expression Profiling
Agrawal et al.
JNCI J Natl Cancer Inst 2002;94:513-521.
ABSTRACT | FULL TEXT  

Identification of Nuclear Matrix Protein Alterations Associated with Human Colon Cancer
Brunagel et al.
Cancer Res. 2002;62:2437-2442.
ABSTRACT | FULL TEXT  

Ectopic Expression of Guanylyl Cyclase C in CD34+ Progenitor Cells in Peripheral Blood
Fava et al.
JCO 2001;19:3951-3959.
ABSTRACT | FULL TEXT  

Routine Chest Roentgenography Is Unnecessary in the Work-Up of Stage I and II Breast Cancer
Chen et al.
JCO 2000;18:3503-3506.
ABSTRACT | FULL TEXT  

FDG PET and Immunoscintigraphy with 99mTc-Labeled Antibody Fragments for Detection of the Recurrence of Colorectal Carcinoma
Willkomm et al.
JNM 2000;41:1657-1663.
ABSTRACT | FULL TEXT  

A New Approach for Clinical Biological Assay Comparison and Standardization: Application of Principal Component Analysis to a Multicenter Study of Twenty-One Carcinoembryonic Antigen Immunoassay Kits
Rymer et al.
Clin. Chem. 1999;45:869-881.
ABSTRACT | FULL TEXT  

Surgical Treatment and Other Regional Treatments for Colorectal Cancer Liver Metastases
Yoon and Tanabe
The Oncologist 1999;4:197-208.
ABSTRACT | FULL TEXT  

Whole-Body PET Imaging With [18F]Fluorodeoxyglucose in Management of Recurrent Colorectal Cancer
Valk et al.
Arch Surg 1999;134:503-511.
ABSTRACT | FULL TEXT  

Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues
Carrithers et al.
Proc. Natl. Acad. Sci. USA 1996;93:14827-14832.
ABSTRACT | FULL TEXT  

Cost of Patient Follow-up After Potentially Curative Colorectal Cancer Treatment
Virgo et al.
JAMA 1995;273:1837-1841.
ABSTRACT  

CEA to Detect Recurrence of Colon Cancer
Northover et al.
JAMA 1994;272:31-31.
ABSTRACT  

Surveillance Scanning of Children with Medulloblastoma
Torres et al.
NEJM 1994;330:892-895.
ABSTRACT | FULL TEXT  

CEA for Monitoring Colon Cancer
Corman and Prager
JAMA 1994;271:346-346.
ABSTRACT  

CEA for Monitoring Colon Cancer
Chu et al.
JAMA 1994;271:345-346.
ABSTRACT  

CEA for Monitoring Colon Cancer
Cohen and Paty
JAMA 1994;271:346-346.
ABSTRACT  

National Policy Development for the Clinical Application of Genetic Diagnostic Technologies: Lessons From Cystic Fibrosis
Wilfond and Nolan
JAMA 1993;270:2948-2954.
ABSTRACT  

CEA Monitoring Has Little Value in Colon Cancer
Journal Watch Dermatology 1993;1993:12-12.
FULL TEXT  

DOES CEA MONITORING HAVE VALUE IN COLON CANCER?
JWatch General 1993;1993:3-3.
FULL TEXT  

CEA Monitoring After Surgery for Colorectal Cancer: When Is the Evidence Sufficient?
Fletcher
JAMA 1993;270:987-988.
ABSTRACT